JOURNAL ARTICLE

18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies

Sara Sheikhbahaei, Krystyna M Jones, Rudolf A Werner, Roberto A Salas-Fragomeni, Charles V Marcus, Takahiro Higuchi, Steven P Rowe, Lilja B Solnes, Mehrbod S Javadi
Annals of Nuclear Medicine 2019, 33 (5): 351-361
30877561

PURPOSE: This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT for the detection of bone metastases in prostate cancer patients. The performance of 18 F-NaF-PET/CT was compared with other imaging techniques in the same cohort of patients.

METHODS: A systematic search was performed in PubMed/Medline and EMBASE (last Updated, September 28, 2018). Studies with histopathology confirmation and/or clinical/imaging follow-up as reference standard were eligible for inclusion.

RESULTS: A total of 14 studies were included. Twelve studies including 507 patients provided per-patient basis information. The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under the summary receiver operating characteristics curve (AUC) of 18 F-NaF-PET/CT for the detection of bone metastases were 0.98 (95% CI 0.95-0.99), 0.90 (95% CI 0.86-0.93), 123.2 and 0.97, respectively. Seven studies provided the lesion-based accuracy information of 1812 lesions identified on 18 F-NaF-PET/CT with the pooled sensitivity, specificity, DOR and AUC of 0.97 (95% CI 0.95-0.98), 0.84 (95% CI 0.81-0.87), 206.8 and 0.97, respectively. The overall diagnostic performance of 18 F-NaF-PET/CT is superior to 99m Tc-bone scintigraphy (AUC 0.842; P < 0.001; four studies) and 99m Tc-SPECT (AUC 0.896; P < 0.001, four studies). Compared to 18 F NaF-PET/CT, whole-body MRI with diffusion-weighted imaging (DWI) was shown to have lower sensitivity (0.83, 95% CI 0.68-0.93), with no significant difference in the overall performance (AUC 0.947; P = 0.18, four studies).

CONCLUSION: 18 F-NaF-PET/CT has excellent diagnostic performance in the detection of bone metastases in staging and restaging of high-risk prostate cancer patients. The performance of 18 F-NaF-PET/CT is superior to 99m Tc bone scintigraphy and SPECT, and comparable to DWI-MRI.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
30877561
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.